SAINT LAURENT, Quebec, May 9, 2013 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company") announced today that at the Company's Annual General Meeting on May 7, 2013, the Security Holders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 3,308,127 to 5,030,292 or 10% of the Company's issued and outstanding shares as of the record day. The amendment of the Plan is subject to TSX-Venture approval.
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.
IntelGenx Technologies Corp. Ingrid Zerbe Corporate Secretary T: 514-331-7440 (ext. 202) F: 514-331-0436 www.intelgenx.com